. After adjustment for confounders, the difference in bRFS between groups was no longer significant (HR ¼ 0.77; 95% CI, 0.41 to 1.46).
INTRODUCTION AND OBJECTIVES: Active surveillance (AS)
is now an accepted strategy for men with low-risk prostate cancer (PCa). A critical factor for successful AS is the best possible patient selection. However, a recent large retrospective study indicates that currently available AS criteria are limited by a high rate of misclassification. We recently collaborated with a biopsy needle manufacturer, TSK Laboratory, to develop a novel 18-G biopsy instrument based on an existing instrument (PRIMECUTâ II), by extending the side-notch length from 19 to 25 mm and the stroke length from 22 to 28 mm, to take a longer tissue core and to reach the anterior portion of the prostate. In this study, we evaluated utility of the novel biopsy instrument in the selection of patients for AS.
METHODS: A total of 167 PCa patients diagnosed with the long-notch needle (n¼62; long-notch group) or normal-notch needle (n¼105; normal-notch group), who subsequently underwent prostatectomy, were retrospectively analyzed. All patients were diagnosed with 12 transrectal ultrasound-guided standard cores. The sampled core length, correlation between total tumor length in biopsy specimens, and total tumor volume in prostatectomy specimens were compared between the two groups. Gleason score (GS) upgrading was also compared. Prostatectomy specimens of patients who met the criteria of the PRIAS study were compared for the two groups.
RESULTS: The mean length of tissue taken with the long-notch needle was significantly longer than that taken with the normal-notch needle (16.3 vs. 22.4 mm, p<0.001) . The correlation coefficient between total tumor length in biopsy specimens and total tumor volume in prostatectomy specimens of the long-notch group was higher (r¼0.701) than that in the normal-notch group (r¼0.611). GS upgrading in the long-notch group was significantly lower than that in the normal-notch group (25.8 vs. 41.0%, p¼0.0479) Only 1 patient with tumor volume >0.5 cc and GS 4+3 or more was included among the 5 who met the criteria of the PRIAS study in the long-notch group, while 6 patients were included among the 10 who met the criteria in the normal-notch group.
CONCLUSIONS: We developed a novel biopsy instrument with a 25 mm side-notch for longer tissue samples, increased correlation between tumor volume in biopsy and prostatectomy specimens, and decreased GS upgrading. These results suggested the utility of the long-notch needle in the selection of patients for AS.
Source of Funding: none

MP43-15 CLINICAL SIGNIFICANCE OF DETECTION OF PERINEURAL INVASION (PNI) ON A SURVEILLANCE BIOPSY IN FAVORABLE RISK MEN ON ACTIVE SURVEILLANCE
Mufaddal Mamawala*, Patricia Landis, Jonathan Epstein, Bruce Trock, H. Ballentine Carter, Baltimore, MD INTRODUCTION AND OBJECTIVES: 1) Evaluate the association between detection of perineural invasion (PNI) on a surveillance biopsy and grade reclassification (GR or Gleason score (GS) 7) during active surveillance (AS); 2) assess whether the presence of PNI alone should exclude men from AS.
METHODS: The study cohort was 1559 men enrolled in an AS registry from 1995 to 2016, following diagnosis of favorable risk prostate cancer. The outcome of interest was GR on surveillance biopsy. A logistic model was used to evaluate the relationship between PNI and GR on next surveillance biopsy. The predictive accuracy of PNI for GR was compared with a recently published multivariable GR risk prediction tool that included period of diagnosis, age, cancer volume, risk status, PSA density, and number of previous biopsies without GR. Predictive performance was evaluated using concordance statistics (AUC), calibration and decision curve analysis RESULTS: Of 1559 men with a median follow-up of 4 years (IQR 2-7 years), 156 (10%) had PNI detected on at least one surveillance biopsy. Three hundred and nineteen men (20%) had GR. PNI was detected in a significantly higher proportion of men with GR than men without GR (19.7% vs. 7.5%, p ¼ <0.0001). PNI was significantly associated with GR, OR ¼ 2.91 (95% CI, 2.06 -4.10, p ¼ < 0.001; AUC ¼ 0.58) in a univariable analysis. The multivariable prediction tool had an AUC of 0.75 (calibration slope ¼ 0.84) for predicting GR with no significant gain in predictive accuracy by incorporating PNI (AUC of 0.77, calibration slope ¼ 0.86). A decision curve analysis showed a positive net benefit of using multivariable risk prediction tools over PNI alone for future biopsy outcome predictions.
CONCLUSIONS: Shared decisions on AS selection and monitoring should be based on individualized risk assessments from multivariable risk prediction tools rather than presence or absence of a single risk factor. Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 THE JOURNAL OF UROLOGY â e559
Source of Funding: None
MP43-16 VARIATION IN ACTIVE SURVEILLANCE UTILIZATION FOR THE MANAGEMENT OF PROSTATE CANCER IN A REGIONAL COLLABORATIVE
Adam Reese*, Claudette Fonshell, Serge Ginzburg, Thomas Guzzo, Thomas Lanchoney, Bret Marlowe, Marc Smaldone, Edouard Trabulsi, Robert Uzzo, on behalf of the Pennsylvania Urologic Regional Collaborative, Philadelphia, PA INTRODUCTION AND OBJECTIVES: Active surveillance (AS) is gaining increasing acceptance as an effective management strategy for men with low risk prostate cancer. We analyzed a regional prostate cancer collaborative in order to characterize variation in the utilization of AS among practitioners and identify factors influencing AS rates.
METHODS: The Pennsylvania Urologic Regional Collaborative (PURC), established in 2014, is a voluntary collaborative of urology practices in Southeastern Pennsylvania focused on the evaluation and improvement of prostate cancer care. We prospectively identified men with newly diagnosed prostate cancer across 6 academic and private practice sites from PURC, and determined the percentage of men initially managed with AS. Variations in AS rates by individual practitioner were determined for men with NCCN very low or low risk disease. Demographic and clinicopathologic parameters were assessed to determine how these factors influenced AS rates.
RESULTS: Between May 2015 and October 2016, 282 of 1154 (19.6%) men with newly diagnosed prostate cancer underwent AS as initial management strategy, including 82/104 (78.9%) men with NCCN very low and 133/322 (41.3%) with NCCN low risk disease. AS rates stratified by practitioner for men with very low or low risk disease ranged from 11.1% to 100% (Figure 1) . Associations of demographic and clinicopathologic parameters with AS rates are shown in the Table. High PSA, Gleason score, clinical stage, and NCCN risk category were all strongly associated with decreased utilization of AS (all p-values < 0.01).
CONCLUSIONS: Recent data report AS rates as high as 91% and 74% for NCCN very low and low risk prostate cancer, respectively. In the PURC collaborative, we observed lower rates of AS utilization for men with low risk prostate cancer, and significant variation in AS utilization among practitioners. These findings demonstrate the potential importance of quality collaboratives such as PURC in helping to identify variations in care and targets for quality improvement within local markets.
Source of Funding: Data was provided with permission from the Pennsylvania Urologic Regional Collaborative (PURC), funded by participating urology practices and the Partnership for Patient Care, a quality improvement initiative supported by the Health Care Improvement Foundation, Independence Blue Cross, and southeastern Pennsylvania hospitals and health systems.
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